Since its inception in 2017, Unlearn has always been at the forefront of innovation, developing AI-based solutions to overcome major challenges in clinical research. With this latest round of funding, bringing the total amount raised to over $130 million, Unlearn is positioning itself to tackle key issues such as long timelines, slow participant recruitment and patient reluctance to join clinical trials for fear of receiving a placebo.
The revolutionary approach of Unlearn, a company present in the Vintage Altaroc Odyssey 2021, is based on the creation of personalized digital twins for each participant in a clinical trial, predicting their health outcomes under placebo, independently of their actual assignment. This technology makes it possible to set up TwinRCTs (TM), highly powerful clinical trials with smaller control groups, giving a greater number of patients the opportunity to benefit from experimental treatments.
By reducing the time it takes to bring new drugs and therapies to market, Unlearn paves the way for significant improvements in healthcare outcomes for all.
Dr. Charles Fisher, founder and CEO of Unlearn, emphasizes the importance of this new round of funding in pursuing the company's mission: "We are determined to overcome the obstacles and prove the value of digital twin technology. This new injection of capital will enable us not only to strengthen our team, but also to extend our capabilities to other therapeutic areas, while raising awareness of the importance of our work."
In recent years, the clinical research industry has seen the emergence of advanced solutions to its most pressing challenges. However, regulatory constraints have often impeded progress. Unlearn has successfully navigated this complex landscape by partnering with regulatory experts and gaining important qualifications, notably from the European Medicines Agency and the US Food and Drug Administration.
The company is also collaborating with biotech companies and academic institutions to accelerate the evaluation process for new treatments, paving the way for a new era of medical discovery.
*The digital twin is not a robot or a 3D body reproduction, but a data set that mirrors each human organism as closely as possible.
